Co-founder/CEO
Nanograb
Nanograb develops generative AI approaches to design multivalent nanoparticles for cell-selective drug delivery. This platform utilizes cutting-edge binder technology for next-generation targeting capabilities. The resulting technology enables targeted drug treatments for diseases while minimizing off-target side effects.
- Artificial Intelligence
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$500KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Current drug delivery methods often lack precision, leading to systemic exposure and reduced efficacy. This non-specific targeting can result in off-target effects and limit the therapeutic potential of many drugs.
Solution
Nanograb employs AI-driven computational methods to design multivalent nanoparticles that enhance drug targeting to specific areas of the body. By optimizing the combination of binders used in drug formulations, Nanograb's technology enables precise delivery of drugs to targeted tissues or cells. This approach aims to improve treatment efficacy for various diseases while minimizing off-target effects. The platform identifies optimal combinations of binders, facilitating the creation of nanoparticles with enhanced targeting capabilities.
Target Audience
The primary customers are pharmaceutical companies and research institutions seeking to improve drug delivery methods and enhance treatment efficacy.
Features
- AI-driven computational platform for binder selection and optimization
- Design of multivalent nanoparticles for targeted drug delivery
- Enhanced drug targeting to specific areas of the body
- Optimization of binder combinations for improved efficacy